Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Bio-sincerity Secures NMPA Clinical Trial Approval for BIOS0629-109, Novel XPO1 Inhibitor for Advanced Malignant Tumors

Fineline Cube Jul 3, 2026
Company Drug

Novartis Secures EU Approval for Itvisma, First Gene Replacement Therapy for Broad SMA Population Including Patients Two Years and Older

Fineline Cube Jul 3, 2026
Policy / Regulatory

NMPA Issues Guidelines for Temporary Import of Urgently Needed Medical Devices

Fineline Cube Oct 19, 2023

The National Medical Products Administration (NMPA) has released new “Management Requirements for Temporary Import and...

Company

Abbott Reports 8.7% Drop in Q3 2023 Global Sales, Hit by Lower SARS-CoV-2 Test Demand

Fineline Cube Oct 19, 2023

Abbott (NYSE: ABT) published its Q3 2023 financial results this week, reporting a 8.7% year-on-year...

Company Drug

Roche’s Alecensa Shows Unprecedented 76% Improvement in Disease-Free Survival in NSCLC Trial

Fineline Cube Oct 19, 2023

Roche (SWX: ROG) subsidiary Genentech has revealed preliminary but promising results from a Phase III...

Company Deals

Eli Lilly Acquires Mablink Bioscience to Expand Next-Gen ADC Portfolio

Fineline Cube Oct 19, 2023

US pharmaceutical company Eli Lilly (NYSE: LLY) has signed an agreement to acquire France-based Mablink...

Company Deals

Belief BioMed Partners with Takeda for BBM-H901 Commercialization in Asia

Fineline Cube Oct 18, 2023

Shanghai-based gene therapy specialist Belief BioMed Group (BBM) has announced a strategic partnership with Japan’s...

Company Drug

MicuRx Pharmaceuticals Initiates Phase I Study for MRX-5 in Australia

Fineline Cube Oct 18, 2023

Sino-US firm MicuRx Pharmaceuticals Inc. has announced the approval to conduct a Phase I clinical...

Company Drug

GenScript Reports $152 Million in Sales for Carvykti as of September 30, 2023

Fineline Cube Oct 18, 2023

China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that its subsidiary,...

Company Drug

Novartis Launches Leqvio in China at RMB 9,988 per Shot

Fineline Cube Oct 18, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has officially launched its cholesterol-lowering drug, Leqvio (inclisiran), in...

Company Drug

Zhejiang Huahai Pharmaceutical Secures Orphan Drug Designation for HB0034

Fineline Cube Oct 18, 2023

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that it has received orphan...

Company Deals R&D

Merck KGaA Partners with Porton Pharma for Next-Gen ADC Platform Development

Fineline Cube Oct 18, 2023

German pharmaceutical giant Merck KGaA (ETR: MRK) has entered into a strategic partnership with China-based...

Company Medical Device

Lepu Medical Gains NMPA Approval for Semi-Automatic External Defibrillator

Fineline Cube Oct 18, 2023

China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has announced...

Company Drug

BeiGene’s Tislelizumab Shows Promising Results in ESMO Presentations for GC/GEJC and NSCLC

Fineline Cube Oct 18, 2023

China-based biotech BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced two late-breaking presentations...

Company Deals

Bayer Partners with HALO Precision Diagnostics to Develop Gadoquatrane for MRI Applications

Fineline Cube Oct 18, 2023

Germany-based Bayer (ETR: BAYN) has announced a strategic partnership with US radiology expert HALO Precision...

Company Deals

Hong Kong WinHealth Pharma Enters Strategic Partnership with Nippon Shinyaku for Irsogladine

Fineline Cube Oct 18, 2023

Hong Kong-based WinHealth Pharma Group Ltd has announced a strategic partnership with Nippon Shinyaku Co...

Company Deals

Gilead Partners with Assembly Biosciences in $84.8 Million Collaboration for Antiviral Therapies

Fineline Cube Oct 18, 2023

Gilead Sciences (NASDAQ: GILD) has announced a significant 12-year collaboration with antiviral specialist Assembly Biosciences...

Company

J&J Reports Strong Q3 2023 Sales Growth Amid Diverse Business Performance

Fineline Cube Oct 18, 2023

Johnson & Johnson (J&J; NYSE: JNJ) has released its Q3 2023 report, revealing impressive global...

Company Deals

Huadong Medicine Secures Global Licensing Agreement for ATGC-110 Botulinum Toxin A Injection

Fineline Cube Oct 18, 2023

China-based Huadong Medicine Co., Ltd. (SHE: 000963) has announced a strategic licensing agreement with South...

Company Deals

Apeloa Pharmaceutical Enters Ten-Year Partnership with Wuhan Hesheng Technology

Fineline Cube Oct 18, 2023

China-based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd. (SHE: 000739) has announced...

Company Drug

BeiGene Submits Supplementary BLA for Tislelizumab in Small Cell Lung Cancer

Fineline Cube Oct 18, 2023

BeiGene (NASDAQ: BGNE) has announced that its supplementary Biologic License Application (sBLA) for the programmed...

Company Drug

Mabwell to Present Promising Clinical Data at 2023 ESMO Congress

Fineline Cube Oct 18, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has announced that it will present the...

Posts pagination

1 … 482 483 484 … 690

Recent updates

  • Bio-sincerity Secures NMPA Clinical Trial Approval for BIOS0629-109, Novel XPO1 Inhibitor for Advanced Malignant Tumors
  • Novartis Secures EU Approval for Itvisma, First Gene Replacement Therapy for Broad SMA Population Including Patients Two Years and Older
  • Ocumension Therapeutics Secures NMPA Approval for OT-502, China’s First Single-Dose Sustained-Release Intraocular Steroid for Postoperative Inflammation
  • Hotgen Biotech Launches AI Subsidiary to Transform Small Nucleic Acid Drug Discovery
  • Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Bio-sincerity Secures NMPA Clinical Trial Approval for BIOS0629-109, Novel XPO1 Inhibitor for Advanced Malignant Tumors

Company Drug

Novartis Secures EU Approval for Itvisma, First Gene Replacement Therapy for Broad SMA Population Including Patients Two Years and Older

Company Drug

Ocumension Therapeutics Secures NMPA Approval for OT-502, China’s First Single-Dose Sustained-Release Intraocular Steroid for Postoperative Inflammation

Company

Hotgen Biotech Launches AI Subsidiary to Transform Small Nucleic Acid Drug Discovery

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.